Literature DB >> 10412783

Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients.

K Oi1, T Hirano, S Sakai, Y Kawaguchi, T Hosoya.   

Abstract

BACKGROUND: It has been reported that remnant lipoproteins and small, dense low-density lipoproteins (LDLs) are risk factors for cardiovascular disease. To determine whether these risk factors are present in hemodialysis (HD) patients who are suffering from a high incidence of atherosclerotic vascular disease, we measured concentrations of remnant lipoproteins and LDL particle diameter in HD patients and compared these with controls. We also measured lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) that play important roles in the generation of remnant lipoproteins and small, dense LDL, and we correlated these changes with plasma lipoprotein abnormalities in HD patients.
METHODS: Lipoproteins were separated by ultracentrifugation. Apoprotein B in very low-density lipoprotein (VLDL), and intermediate-density lipoprotein (IDL) fractions were measured by a sensitive enzyme-linked immunosorbent assay method. The average LDL particle diameter was measured by gradient gel electrophoresis.
RESULTS: Plasma triglyceride, total cholesterol, and high-density lipoprotein (HDL) cholesterol concentrations were comparable between HD patients and controls, whereas LDL cholesterol was significantly lower in HD patients. The average LDL particle diameter was not significantly different between HD patients and controls. LDL particle diameter was inversely related to plasma triglyceride concentrations in all of the subjects. VLDL triglyceride, VLDL cholesterol, and VLDL apoprotein B were comparable between HD patients and controls. IDL triglyceride, IDL cholesterol, and IDL apoprotein B concentrations were all significantly increased in HD patients compared with those in controls. LPL mass was not altered, but HTGL activity was significantly decreased in HD patients. The HTGL activity was inversely related to IDL concentrations.
CONCLUSIONS: These results suggest that a prominent characteristic of lipoprotein abnormalities in HD patients is a marked increase in IDL particle number. In addition, small, dense LDL is not associated with uremic dyslipidemia. Because HTGLs promote the conversion from IDL to LDL and the generation of lipid-poor LDL, a decrease in HTGL activity may contribute to the accumulation of IDL particle and may prevent small, dense LDL formation in HD patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412783     DOI: 10.1046/j.1523-1755.1999.07159.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  10 in total

Review 1.  Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.

Authors:  Heidi Noels; Michael Lehrke; Raymond Vanholder; Joachim Jankowski
Journal:  Nat Rev Nephrol       Date:  2021-05-10       Impact factor: 28.314

Review 2.  Postprandial lipoprotein metabolism: VLDL vs chylomicrons.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Yoshiharu Tokita; Takeaki Nagamine; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Kimber L Stanhope; Peter J Havel; Mitsuyo Okazaki; Masumi Ai; Akira Tanaka
Journal:  Clin Chim Acta       Date:  2011-04-19       Impact factor: 3.786

Review 3.  Dyslipidemia in patients with chronic kidney disease.

Authors:  Matthew R Hager; Archana D Narla; Lisa R Tannock
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

Review 4.  Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.

Authors:  Mona Khurana; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2015-03-24       Impact factor: 3.714

5.  Effects of hemodialysis on serum lipids and phospholipids of end-stage renal failure patients.

Authors:  C Piperi; C Kalofoutis; M Tzivras; T Troupis; A Skenderis; A Kalofoutis
Journal:  Mol Cell Biochem       Date:  2004-10       Impact factor: 3.396

6.  The impact of haemodialysis-associated variables on lipid profile in Egyptian haemodialysis population.

Authors:  H Abo-Zenah; A Sabry; A Farouk; N Abdelhalim; K El-Sayed; M Sobh
Journal:  Int Urol Nephrol       Date:  2007-02-06       Impact factor: 2.266

Review 7.  Uremic toxins and lipases in haemodialysis: a process of repeated metabolic starvation.

Authors:  Bernd Stegmayr
Journal:  Toxins (Basel)       Date:  2014-04-30       Impact factor: 4.546

8.  Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A cross-sectional study from a regional diabetes cohort.

Authors:  Tsutomu Hirano; Noriyuki Satoh; Rieko Kodera; Takeshi Hirashima; Natsuko Suzuki; Ema Aoki; Taito Oshima; Mitsuru Hosoya; Masahiro Fujita; Toshiyuki Hayashi; Yasuki Ito
Journal:  J Diabetes Investig       Date:  2021-11-02       Impact factor: 3.681

Review 9.  Pathophysiology of Diabetic Dyslipidemia.

Authors:  Tsutomu Hirano
Journal:  J Atheroscler Thromb       Date:  2018-07-12       Impact factor: 4.928

10.  Homocysteine level is positively and independently associated with serum creatinine and urea nitrogen levels in old male patients with hypertension.

Authors:  Qianhong Yang; Youwei Lu; Yanhua Deng; Jiayi Xu; Xi Zhang
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.